Abstract 378P
Background
Pembrolizumab combined with chemotherapy has already become the standard first-line treatment for R/M HNSCC. However, data on pembrolizumab in LA HNSCC remains limited, primarily focusing on monotherapy. This study aimed to analyze and explore the efficacy and safety of pembrolizumab combined with chemotherapy as a neoadjuvant treatment.
Methods
A single center, retrospective real-world study was conducted using the database. We included adult resectable LA HNSCC patients who received pembrolizumab plus TP or DP as neoadjuvant therapy between 2021-09-01 and 2023-06-10. Patients were excluded if their histopathological diagnosis was non-squamous cell carcinoma, had received systemic treatment before. Primary endpoint was ORR, and secondary endpoint were pCR and 1y-DFS.
Results
A Total of 21 patients with resectable LA HNSCC were Included. The baseline showed that the median age was 61. PS=0 (19/21), PS=1 (2/21). The location of primary site: oral was 38.1% (8/21); oropharynx was 33.3% (7/21); hypopharyngeal were 23.8% (5/21); sinus was 4.8% (1/21). TNM stage: stage II was 14.3% (3/21); stage III was 38.1% (8/21); stage IVA was 42.6% (9/21); stage IVB was 4.8% (1/21) . CPS status showed 62.0% (13/21) patients were CPS ≥ 20, 38.1% (8/21)1≤CPS<20. 4 (19.0%) patients received 2 cycles, other patients got 3-5 cycles. No grade ≥3 TRAEs detected during neoadjuvant therapy. ORR was 90.5% (19/21), 3 patients achieved CR, and ORR in CPS≥20 was 100%, while 62.5% in CPS<20. In total 13 (62.0%) patients underwent surgery after neoadjuvant therapy, 4 (19.0%) patients did not undergo surgery but received radiation therapy, and the remaining patients have not yet decided on the follow-up treatment plan. pCR reached 72.7% (8/11), pCR+MPR was 100%, and pCR was 75.0% (6/8) in CPS≥20, 33.3% (1/3) in CPS<20 . pCR (≥3 cycles) was 87.5% (7/8) and pCR(2 cycles) was 33.3% (1/3).1y-DFS data is not yet mature.
Conclusions
This study shows that pembrolizumab combined with chemotherapy as a neoadjuvant therapy for LA HNSCC has excellent short-term curative effect and good security. Patients with high CPS expression and long cycles of treatment can see higher pCR.
Clinical trial identification
Editorial acknowledgement
We thank Hui Li and Binjie Li from MSD China Medical Affair oncology team for giving scientific support to the abstract.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract